(SeaPRwire) –
Relapsed or refractory diffuse large B-cell lymphoma is where good intentions in oncology go to get humbled. Patients who fail first-line therapy face a median overall survival of barely over a year and a five-year survival rate hovering around 30%, based on retrospective Asian data. The market has been waiting for something that moves the needle without the logistical burden of CAR-T manufacturing. That anxiety is exactly the opening Junshi Biosciences is walking through. On October 23, 2026, the Shanghai-based company confirmed first patient dosing in the JS203-003-III-DLBCL study, a randomized, open-label, multicenter Phase 3 trial. This is the first registrational study for JS203, its self-developed recombinant humanized anti-CD20/CD3 bispecific antibody. The trial pits JS203 plus chemotherapy against the incumbent standard of rituximab plus chemotherapy in R/R DLBCL patients. Rituximab has been the backbone of B-cell lymphoma care for two decades. Taking it head-on in a head-to-head registrational design is not a cautious move. It is a declaration.
The facts deserve a careful reading. The study, led by Professor Yuqin Song of Beijing Cancer Hospital, plans to enroll 282 subjects with overall survival as the primary endpoint. OS, not progression-free survival or response rate. That is the hardest bar in oncology and the one regulators and payers actually respect. The Phase 1 foundation is genuinely encouraging. At the recommended Phase 2 dose with step-up dosing to 30 mg, JS203 monotherapy delivered an objective response rate of 72.4% in CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma. Within the DLBCL subgroup specifically, ORR reached 69.7% and complete response rate hit 39.4%, with durable remissions observed. The safety profile is arguably the more interesting number. Cytokine release syndrome occurred in only 27.3% of patients, and there were zero cases of ICANS, the neurotoxicity that has plagued T-cell engagers and complicated community hospital adoption of competitors like glofitamab and epcoritamab. Meanwhile the addressable problem keeps growing. DLBCL accounts for roughly 40% of adult non-Hodgkin lymphoma cases in China, with about 45,000 new diagnoses annually per GLOBOCAN 2022, and incidence is creeping upward.
Now the commercial logic. Junshi already proved with toripalimab, its PD-1 antibody approved across more than 50 countries including the US and Europe, that it can execute global regulatory strategy from a Chinese cost base. JS203 fits the same playbook. Bispecific antibodies are off-the-shelf, meaning no vein-to-vein wait, no manufacturing slots, no six-figure per-patient production economics. If the Phase 3 confirms the Phase 1 signal with a clean CRS and zero-ICANS profile, Junshi owns a product that community oncologists can actually administer, which is where the volume lives in both China and emerging markets. The combination-with-chemotherapy design also matters. It positions JS203 as an upgrade to an existing, reimbursed workflow rather than a wholesale treatment disruption, lowering adoption friction. The end-game here is straightforward. If JS203 beats rituximab on overall survival in this 282-patient trial, the R/R DLBCL treatment algorithm gets rewritten around a Chinese-originated bispecific, and Junshi converts a domestic pipeline asset into a global franchise. Watch the enrollment velocity. That single metric will tell you whether investigators believe the early data, and right now the smart money says they do.